| Date Filed | Type | Description |
| 10/06/2023 |
SC 13G
| VIKING GLOBAL INVESTORS LP reports a 5.1% stake in Five9, Inc. |
| 08/24/2023 |
SC 13G
| VIKING GLOBAL INVESTORS LP reports a 6% stake in Valvoline Inc. |
| 08/14/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 07/19/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 07/19/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/16/2023 |
SC 13D/A
| VIKING GLOBAL INVESTORS LP reports a 7.2% stake in Cazoo Group Ltd. |
| 06/05/2023 |
SC 13G
| VIKING GLOBAL INVESTORS LP reports a 7.9% stake in Verastem, Inc. |
| 05/16/2023 |
SC 13D/A
| VIKING GLOBAL INVESTORS LP reports a 7.2% stake in Cazoo Group Ltd. |
| 05/11/2023 |
4
| VIKING GLOBAL INVESTORS LP (10% Owner) has filed a Form 4 on 4D Molecular Therapeutics, Inc.|
Txns:
| Bought 850,000 shares
@ $16, valued at
$13.6M
|
|
| 04/27/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 03/21/2023 |
SC 13D/A
| VIKING GLOBAL INVESTORS LP reports a 7.2% stake in Cazoo Group Ltd. |
| 02/27/2023 |
SC 13D/A
| VIKING GLOBAL INVESTORS LP reports a 7.2% stake in Cazoo Group Ltd. |
| 02/14/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 02/14/2023 |
SC 13G/A
| VIKING GLOBAL INVESTORS LP reports a 9.7% stake in Pharvaris N.V. |
| 02/14/2023 |
SC 13G/A
| VIKING GLOBAL INVESTORS LP reports a 4% stake in Guardant Health, Inc. |
| 02/14/2023 |
SC 13G/A
| VIKING GLOBAL INVESTORS LP reports a 7% stake in Amylyx Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| VIKING GLOBAL INVESTORS LP reports a 10% stake in Trevi Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| VIKING GLOBAL INVESTORS LP reports a 15.2% stake in Inhibrx, Inc. |
| 02/14/2023 |
SC 13G/A
| VIKING GLOBAL INVESTORS LP reports a 0% stake in FIGS, Inc. |
| 02/14/2023 |
SC 13G/A
| VIKING GLOBAL INVESTORS LP reports a 17.4% stake in APi Group Corporation |
| 02/14/2023 |
SC 13G/A
| VIKING GLOBAL INVESTORS LP reports a 9.5% stake in Standard BioTools Inc. |
| 02/14/2023 |
SC 13G/A
| VIKING GLOBAL INVESTORS LP reports a 9.4% stake in Ginkgo Bioworks Holdings, Inc. |
| 02/14/2023 |
SC 13G/A
| VIKING GLOBAL INVESTORS LP reports a 0% stake in COUPA SOFTWARE INCORPORATED |
| 02/14/2023 |
SC 13G/A
| VIKING GLOBAL INVESTORS LP reports a 6.5% stake in PepGen Inc. |
| 02/14/2023 |
SC 13G/A
| VIKING GLOBAL INVESTORS LP reports a 0% stake in Celldex Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| VIKING GLOBAL INVESTORS LP reports a 0% stake in PROCEPT BioRobotics Corporation |
| 02/14/2023 |
SC 13G/A
| VIKING GLOBAL INVESTORS LP reports a 7% stake in Edgewise Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| VIKING GLOBAL INVESTORS LP reports a 0% stake in Orion Acquisition Corp. |
| 11/25/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 11/25/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/14/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 11/10/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 11/04/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|